Influence of acute and chronic kidney failure in rats on the disposition and pharmacokinetics of ZYAN1, a novel prolyl hydroxylase inhibitor, for the treatment of chronic kidney disease-induced anemia-Reference-Cited by-同舟云学术

Influence of acute and chronic kidney failure in rats on the disposition and pharmacokinetics of ZYAN1, a novel prolyl hydroxylase inhibitor, for the treatment of chronic kidney disease-induced anemia

Published:2017-01-19 Issue:1 Volume:48 Page:37-44
ISSN:0049-8254
Container-title:Xenobiotica
language:en
Short-container-title:Xenobiotica

Author:

Patel Harilal¹,Joharapurkar Amit Arvind²,Pandya Vrajesh Bhaskarbhai³,Patel Vishal Jagjivanbhai²,Kshirsagar Samadhan Govind²,Patel Prakash¹,Gevriya Bhavesh¹,Jain Mukul R.²,Srinivas Nuggehally R.¹,Patel Pankaj Ramanbhai¹²³,Desai Ranjit C.³

Affiliation:

1. Department of Drug Metabolism and Pharmacokinetics,

2. Department of Pharmacology and Toxicology, and

3. Department of Medicinal chemistry, Zydus Research Centre, Cadila Healthcare Limited, Ahmedabad, India

Publisher

Informa UK Limited

Subject

Health, Toxicology and Mutagenesis,Pharmacology,Toxicology,Biochemistry,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/00498254.2016.1278287

Reference28 articles.

1. Buch A, Maroni B, Hartman C. (2015). Dose exposure relationship of vadadustat is independent of the level of renal function. American Society of Nephrology Kidney Week Annual Meeting; 2015 Nov 3–8; San Diego, CA, USA (Abstract Program #SA-PO537)

2. Chronic kidney disease after acute kidney injury: a systematic review and meta-analysis

3. The Patterns, Risk Factors, and Prediction of Progression in Chronic Kidney Disease: A Narrative Review

4. Role of hepcidin in the pathophysiology and diagnosis of anemia

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Hypoxia and panvascular diseases: exploring the role of hypoxia-inducible factors in vascular smooth muscle cells under panvascular pathologies;Science Bulletin;2023-09

2. Impact of Disease States on the Oral Pharmacokinetics of EIDD-1931 (an Active Form of Molnupiravir) in Rats for Implication in the Dose Adjustment;Molecular Pharmaceutics;2023-08-01

3. Nonclinical Pharmacokinetic Evaluation of Desidustat: a Novel Prolyl Hydroxylase Inhibitor for the Treatment of Anemia;European Journal of Drug Metabolism and Pharmacokinetics;2022-07-26

4. Desidustat: First Approval;Drugs;2022-07

5. Prolyl hydroxylase inhibitor desidustat protects against acute and chronic kidney injury by reducing inflammatory cytokines and oxidative stress;Drug Development Research;2021-01-22